AveXis, Inc. (NASDAQ:AVXS) insider Brian K. Kaspar sold 15,000 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $101.46, for a total transaction of $1,521,900.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of AveXis, Inc. (AVXS) traded up 1.44% during trading on Wednesday, reaching $102.69. The company’s stock had a trading volume of 388,169 shares. The company’s 50 day moving average price is $94.44 and its 200 day moving average price is $83.18. AveXis, Inc. has a 12 month low of $43.06 and a 12 month high of $104.86. The firm’s market cap is $3.28 billion.

AveXis (NASDAQ:AVXS) last announced its earnings results on Thursday, August 10th. The company reported ($2.07) EPS for the quarter, missing the consensus estimate of ($0.97) by ($1.10). During the same quarter in the prior year, the company posted ($0.68) earnings per share. On average, equities analysts predict that AveXis, Inc. will post ($6.22) earnings per share for the current year.

WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/11/avexis-inc-avxs-insider-sells-1521900-00-in-stock.html.

Several brokerages have recently issued reports on AVXS. Chardan Capital set a $103.00 price target on shares of AveXis and gave the company a “buy” rating in a report on Sunday, June 18th. Sanford C. Bernstein assumed coverage on shares of AveXis in a report on Thursday, July 27th. They issued an “outperform” rating and a $108.00 price objective for the company. Evercore ISI started coverage on shares of AveXis in a report on Wednesday, August 16th. They issued an “outperform” rating and a $120.00 price objective for the company. BMO Capital Markets reiterated an “outperform” rating and issued a $123.00 price target on shares of AveXis in a research report on Saturday, September 30th. Finally, Zacks Investment Research upgraded shares of AveXis from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $106.31.

A number of large investors have recently made changes to their positions in AVXS. Russell Investments Group Ltd. raised its stake in shares of AveXis by 41.7% in the second quarter. Russell Investments Group Ltd. now owns 24,871 shares of the company’s stock worth $2,043,000 after purchasing an additional 7,321 shares during the last quarter. Tocqueville Asset Management L.P. purchased a new stake in shares of AveXis during the second quarter valued at approximately $552,000. TimesSquare Capital Management LLC purchased a new stake in shares of AveXis during the second quarter valued at approximately $6,162,000. Credit Suisse AG increased its position in shares of AveXis by 36.4% during the first quarter. Credit Suisse AG now owns 63,228 shares of the company’s stock valued at $4,807,000 after acquiring an additional 16,876 shares during the last quarter. Finally, Swiss National Bank increased its position in shares of AveXis by 3.0% during the first quarter. Swiss National Bank now owns 27,400 shares of the company’s stock valued at $2,083,000 after acquiring an additional 800 shares during the last quarter. Institutional investors and hedge funds own 94.71% of the company’s stock.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Insider Buying and Selling by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.